Role of TFEB-driven autophagy regulation in pancreatic cancer treatment.
KATHRIN KLEIN , KRISTIN WERNER , CHRISTIAN TESKE , MIRIAM SCHENK
International Journal of Oncology 49 ( 1) 164 -172
15
2016
Preparation of acariogenic sugar substitutes
Markwart Kunz , Ralf Mattes , Kathrin Klein , Mohammed Munir
12
2003
Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells
Ulrich M Zanger , Kathrin Klein , Kathrin Klein , Ute Hofmann
Scientific Reports 11 ( 1) 1000
2021
Genetic polymorphisms of glutathione S‐transferase A1, the major glutathione S‐transferase in human liver: Consequences for enzyme expression and busulfan conjugation
Monika Bredschneider , Kathrin Klein , Thomas E. Mürdter , Claudia Marx
Clinical Pharmacology & Therapeutics 71 ( 6) 479 -487
71
2002
Bioactivation of chlorpyrifos by CYP2B6 variants
Alice L. Crane , Kathrin Klein , James R. Olson
Xenobiotica 42 ( 12) 1255 -1262
10
2012
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Ulrich M. Zanger , Miia Turpeinen , Kathrin Klein , Matthias Schwab
Analytical and Bioanalytical Chemistry 392 ( 6) 1093 -1108
417
2008
Importance of Pharmacogenomics
Ulrich M. Zanger , Kathrin Klein , Jessica Rieger
Metabolism of Drugs and Other Xenobiotics 259 -284
2012
Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group
Matthias Schwab , Ulrich M. Zanger , Claudia Marx , Elke Schaeffeler
Journal of Clinical Oncology 26 ( 13) 2131 -2138
307
2008
Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem.
Kathrin Klein , Ulrich M. Zanger
Frontiers in Genetics 4 12 -12
131
2013
Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance
Ulrich M. Zanger , Kathrin Klein
Frontiers in Genetics 4 24 -24
192
2013
Functional polymorphisms of xenobiotics metabolizing enzymes-a research topic.
José A. G. Agúndez , Kathrin Klein
Frontiers in Genetics 4 79 -79
1
2013
Rapid CYP450 quantification by immunoaffinity-mass spectrometry
Oliver Pötz , Helen Hammer , Felix Schmidt , Kathrin Klein
Drug Metabolism and Pharmacokinetics 34 ( 1)
2019
Epigenetics and MicroRNAs in Pharmacogenetics.
Ulrich M. Zanger , Kathrin Klein , Nicole Kugler , Tamara Petrikat
Advances in pharmacology (San Diego) 83 33 -64
4
2018
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Ulrich M Zanger , Kathrin Klein , Tanja Saussele , Julia Blievernicht
Pharmacogenomics 8 ( 7) 743 -759
227
2007
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes
Markus Schirmer , Albert Rosenberger , Kathrin Klein , Bettina Kulle
Pharmacogenomics 8 ( 5) 443 -453
77
2007
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Zeruesenay Desta , Tanja Saussele , Bryan Ward , Julia Blievernicht
Pharmacogenomics 8 ( 6) 547 -558
251
2007
A New Panel-Based Next-Generation Sequencing Method for ADME Genes Reveals Novel Associations of Common and Rare Variants With Expression in a Human Liver Cohort.
Kathrin Klein , Roman Tremmel , Stefan Winter , Sarah Fehr
Frontiers in Genetics 10 7
17
2019
Impact of Genetic Polymorphism in Relation to Other Factors on Expression and Function of Human Drug-Metabolizing P450s
Ulrich M. Zanger , Kathrin Klein , Tanja Richter , Claudia Toscano
Toxicology Mechanisms and Methods 15 ( 2) 121 -124
15
2005
MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms
Julia K Blievernicht , Elke Schaeffeler , Kathrin Klein , Michel Eichelbaum
Clinical Chemistry 53 ( 1) 24 -33
35
2007
MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation.
Nicole Kugler , Kathrin Klein , Ulrich M. Zanger
Biochemical Pharmacology 171 113725
10
2020